XML 61 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions (Details Textual)
1 Months Ended 12 Months Ended
Jul. 07, 2017
$ / shares
shares
Jul. 06, 2017
USD ($)
Jan. 29, 2018
USD ($)
Sep. 15, 2016
USD ($)
a
ft²
Jul. 31, 2016
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
Dec. 31, 2015
Research and Development Expense           $ 3,816,732 $ 2,966,165  
Minority Interest Ownership Percentage In Company           5.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares           897,747    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares           $ 1.95    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares           $ 1.77 $ 1.16  
Net Rentable Area | a       953        
Lessee, Operating Lease, Renewal Term           2 years    
Related Parties, Ownership Interest Percentage               5.00%
Vice President of Research and Development [Member]                
Research and Development Expense           $ 1,155,500 $ 1,427,958  
Officers Compensation per Month   $ 9,167            
Officers Compensation per Hour   175            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares 100,264              
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares $ 1.95              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 36 months              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 173,900              
Net Rentable Area | ft²       953        
Lease, Monthly Base Rent       $ 3,895        
Lessee, Operating Lease, Expiry date       Sep. 14, 2018        
Lessee, Operating Lease, Renewal Term       2 years        
Operating Lease, Expense           45,678 18,590  
Security Deposit           3,895    
Leasehold Improvements, Gross           40,000    
Vice President of Research and Development [Member] | Subsequent Event [Member]                
Officers' Compensation     $ 165,000          
Senju Pharmaceutical Co [Member]                
Royalty Income, Percentage               5.00%
License Agreement, Expiry Period, Description               The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents.
Research and Development Expense [Member] | Vice President of Research and Development [Member]                
Due to Related Parties           94,998    
Related to expenses incurred           9,906    
Chief Executive Officer [Member]                
Office space expenses         $ 3,000      
Operating Leases, Rent Expense           36,000 18,000  
Cura Partners [Member] | Consulting Agreement [Member]                
Consulting agreement payment, Permonth   9,567            
Consulting agreement payment, Perhour   $ 250            
Cura Partners [Member] | General and Administrative Expense [Member] | Consulting Agreement [Member]                
Related Party Transaction, Expenses from Transactions with Related Party           85,835    
Private Medical Equity, Inc. [Member]                
Consulting Fee           33,200    
Private Medical Equity, Inc. [Member] | Consulting Agreement [Member]                
Related Party Transaction, Expenses from Transactions with Related Party           329,400 398,400  
Private Medical Equity, Inc. [Member] | Research and Development Expense [Member] | Consulting Agreement [Member]                
Related Party Transaction, Expenses from Transactions with Related Party           176,344 318,720  
Private Medical Equity, Inc. [Member] | General and Administrative Expense [Member] | Consulting Agreement [Member]                
Related Party Transaction, Expenses from Transactions with Related Party           152,656 79,680  
Beneficial Owner [Member] | Research and Development Expense [Member] | Consulting Agreement [Member]                
Related Party Transaction, Expenses from Transactions with Related Party           $ 0 $ 366,209